The misuse and overuse of antibiotics has impacted their effectiveness globally. Diagnostics that detect infection and genetic markers for antibiotic resistance in a single test enable you to implement Resistance Guided Therapy (RGT). Utilising an RGT approach is clinically demonstrated to improve patient cure rates1 and is recommended by international bodies as the preferred method of treatment for infections such as Mycoplasma genitalium (Mgen) or gonorrhoea.2-6
Watch the video to learn about Chris and Luke: two patients who contracted Mycoplasma genitalium infections but with very different personal stories.
Without access to RGT, Luke experienced delays in diagnosis and incorrect treatment regimes which resulted in extended time living with uncomfortable symptoms.
Chris was able to access RGT at his first clinic visit. His Mgen test result indicated he had a resistance infection so he received the appropriate second-line treatment straight away, reducing his time to cure.
RGT can positively impact patient outcome while reducing overall healthcare costs associated with return patient visits and failed treatments.
Resistance Guided Therapy achieves better cure rates for Mycoplasma genitalium (Mgen)
Reference: Read TRH et al. Clinical Infectious Diseases 2019; 68(4):554-560
Guidelines for management of infectious diseases are moving away from empiric treatment pathways towards more directed use of antibiotics. Following RGT practices can positively impact patient cure rates while reducing overall healthcare costs.
Data from Melbourne Sexual Health Centre demonstrated successful increase in cure rate when using RGT compared with previously used Mgen-detection only approach. Substituting azithromycin with doxycycline for empiric treatment, with subsequent treatment of Mgen infections based on resistance result, cure rates increased from below 67% to ≥92%:
Action is urgently needed to improve the management of gonorrhea, including strategies to preserve the efficacy of ceftriaxone, one of the last remaining antibiotics available for multi-drug resistant infections. Surveillance data indicates that in some regions up to 7 out of 10 infections could be effectively treated with a single, more convenient oral dose of ciprofloxacin if the susceptibility status is established prior to prescribing.
*Recommendations by British Association of Sexual Health and HIV (BASHH).
We are committed to supporting continued scientific discovery and generation of clinically relevant data. Collaborations with key researchers and clinicians around the globe help us improve diagnostics and address urgent clinical needs.
The Value of Molecular Tests to Diagnose and Detect Ciprofloxacin Susceptible Gonorrhoea in Clinical Practice
Lewis D et al. SpeeDx Satellite Symposium (IUSTI Asia Pacific Sexual Health Congress) Nov 2, 2018, Auckland, New Zealand.
Provides background on gonorrhoea treatment options and speaks about the clinical utility of Resistance Guided Therapy in the context of ciprofloxacin susceptibility testing when treating gonorrhoea.
Evolution of Resistance Guided Therapy
Bradshaw C et al. SpeeDx and Cepheid Joint Satellite Symposium (Australasian Sexual Health Conference) September 16, 2019.
Discussion on the value of Resistance Guided Therapy in the clinic, including experiences of early access to ResistancePlus® MG FleXible – near patient macrolide resistance testing for Mgen infections – and the expected impact of near-patient testing.
Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation
Read TRH et al. Clinical Infectious Diseases, Volume 68, Issue 4, 15 February 2019, Pages 554–560.
The seminal publication demonstrating significant improvements to Mgen infection cure rate through the use of doxycycline for emperic treatment and implementation of ResistancePlus® MG to guide subsequent treatment decisions. Cure rates improved from below 60% to over 92%.
“The overall concept is that with rapid detection of Neisseria gonorrhoeae, and detection of key antimicrobial resistant genes, we can enable doctors to do targeted treatment, which will reduce antibiotic selection pressure and decrease the emergence of resistance.”
“Local AMR testing and surveillance as well as diagnostic tests for M. genitalium need to become routinely available and should ideally be supplemented with molecular detection of mutations that mediate macrolide resistance. Such assays will substantially improve patient management.”